Usage of Aripiprazole Intermediates 129722-34-5

Aripiprazole tablets, indications for the treatment of schizophrenia. Short-term (4-week and 6-week) controlled trials of schizophrenics established the efficacy of aripiprazole in the treatment of schizophrenia. Physicians who choose aripiprazole for long-term treatment should periodically re-evaluate the drug's long-term efficacy in individual patients.

Compared with placebo, the use of atypical antipsychotics for Alzheimer's related psychosis increases the risk of death. Seventeen placebo-controlled studies of similar drugs found that the mortality rate in the drug-treated group was 1.6 to 1.7 times that in the placebo group. The mortality rate for the drug-treated group in a typical 10-week placebo-controlled trial was 4.5% compared to the 2.6% mortality in the placebo group. Although the cause of death varies, most seem to be associated with cardiovascular disease (such as heart failure or sudden death) or infection (such as pneumonia). Aripiprazole can not be used for the treatment of dementia-related psychosis.

MORE_DETAIL Aripiprazole Intermediates 129722-34-5

Basic Information of Aripiprazole Intermediates 129722-34-5

CAS No. of intermediates: 129722-34-5

Other Names: 7-(4-Bromobutoxy)-3,4-dihydro-2(1H)-quinolinone

MF: C13H16BrNO2

MW: 298.18

Melting point: 110-111°C

Purity: 99.0%min

Application: Pharm Intermediates

Appearance: White crystalline powder, White crystalline powder

Item:129722-34-5 & other Aripiprazole intermediates

Shelf life: 2 years

Usage of Aripiprazole Intermediates 129722-34-5

Aripiprazole tablets, indications for the treatment of schizophrenia. Short-term (4-week and 6-week) controlled trials of schizophrenics established the efficacy of aripiprazole in the treatment of schizophrenia. Physicians who choose aripiprazole for long-term treatment should periodically re-evaluate the drug's long-term efficacy in individual patients.

Compared with placebo, the use of atypical antipsychotics for Alzheimer's related psychosis increases the risk of death. Seventeen placebo-controlled studies of similar drugs found that the mortality rate in the drug-treated group was 1.6 to 1.7 times that in the placebo group. The mortality rate for the drug-treated group in a typical 10-week placebo-controlled trial was 4.5% compared to the 2.6% mortality in the placebo group. Although the cause of death varies, most seem to be associated with cardiovascular disease (such as heart failure or sudden death) or infection (such as pneumonia). Aripiprazole can not be used for the treatment of dementia-related psychosis.